LifeStance Health Gr Analyst Ratings
LifeStance Health Gr Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 08/10/2023 | 20.77% | JP Morgan | $9 → $10 | Maintains | Neutral |
| 07/13/2023 | 20.77% | Morgan Stanley | $10 → $10 | Reiterates | Overweight → Overweight |
| 05/19/2023 | 8.7% | Goldman Sachs | $8 → $9 | Maintains | Neutral |
| 05/11/2023 | 20.77% | Morgan Stanley | $8 → $10 | Maintains | Overweight |
| 01/06/2023 | -3.38% | Morgan Stanley | → $8 | Upgrades | Equal-Weight → Overweight |
| 11/15/2022 | -3.38% | Goldman Sachs | $9 → $8 | Maintains | Neutral |
| 11/14/2022 | -3.38% | Cowen & Co. | $10 → $8 | Maintains | Outperform |
| 11/07/2022 | — | Jefferies | Assumes | → Buy | |
| 08/22/2022 | 20.77% | Cowen & Co. | $11 → $10 | Maintains | Outperform |
| 05/10/2022 | -3.38% | Morgan Stanley | $10 → $8 | Maintains | Equal-Weight |
| 03/21/2022 | 20.77% | Goldman Sachs | $15 → $10 | Maintains | Neutral |
| 03/17/2022 | 20.77% | UBS | $19 → $10 | Downgrades | Buy → Neutral |
| 12/17/2021 | 20.77% | Morgan Stanley | $15 → $10 | Maintains | Equal-Weight |
| 11/09/2021 | 44.93% | JP Morgan | $24 → $12 | Downgrades | Overweight → Neutral |
| 09/10/2021 | 117.39% | Cowen & Co. | → $18 | Initiates Coverage On | → Outperform |
| 08/16/2021 | 93.24% | Morgan Stanley | $36 → $16 | Downgrades | Overweight → Equal-Weight |
| 07/06/2021 | 310.63% | UBS | → $34 | Initiates Coverage On | → Buy |
| 07/06/2021 | — | William Blair | Initiates Coverage On | → Outperform | |
| 07/06/2021 | 334.78% | Morgan Stanley | → $36 | Initiates Coverage On | → Overweight |
| 07/06/2021 | 334.78% | JP Morgan | → $36 | Initiates Coverage On | → Overweight |
| 07/06/2021 | 201.93% | Goldman Sachs | → $25 | Initiates Coverage On | → Neutral |
| 日期 | 上行/下行 | 分析公司 | 目標價格變化 | 評級變化 | 上一次/當前評級 |
|---|---|---|---|---|---|
| 2023年08月10日 | 20.77% | 摩根大通 | $9→$10 | 維護 | 中性 |
| 07/13/2023 | 20.77% | 摩根士丹利 | $10→$10 | 重申 | 超重→超重 |
| 2023年05月19日 | 8.7% | 高盛 | $8→$9 | 維護 | 中性 |
| 2023年05月11日 | 20.77% | 摩根士丹利 | $8→$10 | 維護 | 超重 |
| 01/06/2023 | -3.38% | 摩根士丹利 | →$8 | 升級 | 等重→超重 |
| 2022年11月15日 | -3.38% | 高盛 | $9→$8 | 維護 | 中性 |
| 2022年11月14日 | -3.38% | 考恩公司 | $10→$8 | 維護 | 跑贏大盤 |
| 11/07/2022 | - | 傑富瑞 | 假設 | →購買 | |
| 2022/08/22 | 20.77% | 考恩公司 | $11→$10 | 維護 | 跑贏大盤 |
| 2022年05月10日 | -3.38% | 摩根士丹利 | $10→$8 | 維護 | 等重 |
| 03/21/2022 | 20.77% | 高盛 | $15→$10 | 維護 | 中性 |
| 03/17/2022 | 20.77% | 瑞銀集團 | $19→$10 | 評級下調 | 購買→中性 |
| 2021/12/17 | 20.77% | 摩根士丹利 | $15→$10 | 維護 | 等重 |
| 11/09/2021 | 44.93% | 摩根大通 | $24→$12 | 評級下調 | 超重→中性 |
| 09/10/2021 | 117.39% | 考恩公司 | →$18 | 開始承保 | →跑贏大盤 |
| 08/16/2021 | 93.24% | 摩根士丹利 | $36→$16 | 評級下調 | 超重→等重 |
| 07/06/2021 | 310.63% | 瑞銀集團 | →$34 | 開始承保 | →購買 |
| 07/06/2021 | - | 威廉·布萊爾 | 開始承保 | →跑贏大盤 | |
| 07/06/2021 | 334.78% | 摩根士丹利 | →$36 | 開始承保 | →超重 |
| 07/06/2021 | 334.78% | 摩根大通 | →$36 | 開始承保 | →超重 |
| 07/06/2021 | 201.93% | 高盛 | →$25 | 開始承保 | →中性 |
What is the target price for LifeStance Health Gr (LFST)?
LifeStance Health Gr(LFST)的目標價格是多少？
The latest price target for LifeStance Health Gr (NASDAQ: LFST) was reported by JP Morgan on August 10, 2023. The analyst firm set a price target for $10.00 expecting LFST to rise to within 12 months (a possible 20.77% upside). 9 analyst firms have reported ratings in the last year.
摩根大通於2023年8月10日報道了LifeStance Health Gr(納斯達克：LFST)的最新目標價。這家分析公司將目標價定為10.00美元，預計LFST將在12個月內升至(可能上漲20.77%)。去年有9家分析公司公佈了評級。
What is the most recent analyst rating for LifeStance Health Gr (LFST)?
LifeStance Health Gr(LFST)的最新分析師評級是多少？
The latest analyst rating for LifeStance Health Gr (NASDAQ: LFST) was provided by JP Morgan, and LifeStance Health Gr maintained their neutral rating.
分析師對LifeStance Health Gr(納斯達克代碼：LFST)的最新評級由摩根大通提供，LifeStance Health Gr維持中性評級。
When is the next analyst rating going to be posted or updated for LifeStance Health Gr (LFST)?
LifeStance Health Gr(LFST)的下一次分析師評級將於何時發佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of LifeStance Health Gr, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for LifeStance Health Gr was filed on August 10, 2023 so you should expect the next rating to be made available sometime around August 10, 2024.
分析師在進行了廣泛的研究後得出股票評級，其中包括查閱公共財務報表，與LifeStance Health Gr的高管和客戶交談，以及聽取收益電話會議。大多數分析師每三個月就會這樣做一次，所以你每年應該會得到每家公司每家公司的4個評級。LifeStance Health Gr的上一次評級是在2023年8月10日提交的，所以你應該預計下一次評級將在2024年8月10日左右提供。
Is the Analyst Rating LifeStance Health Gr (LFST) correct?
分析師對LifeStance Health Gr(LFST)的評級正確嗎？
While ratings are subjective and will change, the latest LifeStance Health Gr (LFST) rating was a maintained with a price target of $9.00 to $10.00. The current price LifeStance Health Gr (LFST) is trading at is $8.28, which is out of the analyst's predicted range.
雖然評級是主觀的，並將發生變化，但最新的LifeStance Health Gr(LFST)評級保持不變，目標價在9.00美元至10.00美元之間。LifeStance Health Gr(LFST)目前的交易價格為8.28美元，超出了分析師的預測區間。
譯文內容由第三人軟體翻譯。